Partners: ANR, ISCIII, Ministero della Salute, DLR
The potential of Personalised Medicine (PM) is to improve prevention, diagnosis and treatment of diseases by taking into account individuals' genotypes and phenotypes as well as other biomedical, life style and environmental data. In the last decade, significant advancements have been made especially for cancer or rare diseases. However, due to fragmentation and high upfront-investments the implementation of PM remains challenging, besides the various ongoing research and implementation actions on European, national and regional level. To overcome these hurdles, the International Consortium for Personalised Medicine (ICPerMed) is currently being initiated as a joint endeavour of the European Commission (EC) and more than 20 Member States. ICPerMed aims at aligning present as well as future efforts in all areas of PM by fostering international coordination of research and innovation funding. For this purpose, ICPerMed will develop and operate a European platform for collaboration between funders of PM research. It will promote an interdisciplinary approach to PM and generate policies, best practices, guidelines, and standards. ICPerMed secretariat will substantially contribute to the success of ICPerMed by efficiently coordinating all consortium activities, by implementing an effective dissemination plan and by assisting in the development of a sustainability strategy. By monitoring ongoing research funding activities in Europe and beyond, the secretariat will serve as the basis for evidence-informed allocation of research funding. ICPerMed secretariat will provide professional support in organising ICPerMed events and the meetings of ICPerMed bodies. In addition, ICPerMed secretariat will guide the dialogue with relevant stakeholders and initiatives. The organisational and logistical support of a secretariat will maximise the unique and long-term impact of ICPerMed by strengthening Europe's leading role in the successful implementation of PM in the global context.
Partners: Ministero della Salute, ANR, DLR, ISCIII
The potential of personalised medicine (PM) is to improve prevention, diagnosis and treatment of diseases by taking into account individuals' genotypes and phenotypes as well as other biomedical, life style and environmental data. However, with some exceptions in cancer and rare diseases, PM has not yet arrived in clinical practice due to fragmentation, undefined legal and regulatory frameworks and its unclear economic value. To overcome these hurdles, ICPerMed was founded to initiate and support communication and exchange on PM research, funding and implementation. ICPerMed provides a platform to identify the requirements for a suitable framework in terms of infrastructures, resources and regulatory procedures to foster the development and implementation of PM. The ICPerMed Secretariat will continue to substantially contribute to the success of ICPerMed by efficiently coordinating all consortium activities. This includes supporting the ICPerMed governance and working groups as well as organising ICPerMed internal meetings and thematic events. A further important task of the ICPerMed Secretariat will be the implementation of an effective dissemination plan and the assistance in the development of a sustainability strategy. By monitoring ongoing research funding activities and collecting “Best Practice Examples”, the secretariat will provide the basis for evidence informed allocation of research funding and regulatory framework and standard development. The ICPerMed Secretariat will guide the dialogue with relevant stakeholders and initiatives. It will support training measures in PM in order to facilitate implementation of PM into practice. The organisational and logistical support of a secretariat will maximise the unique and long-term impact of ICPerMed by strengthening Europe's leading role in the successful implementation of PM in the global context.
TAIPI, Tools and Actions for Impact Assessment and Policy makers Information, is a CSA proposal to the “Policy environment for FET Flagships” topic of the call H2020-FETFLAG-2014. TAIPI addresses the scope of the this topic by undertaking actions related to: (i) Assessing the impacts of FET Flagship initiatives, including through metrics and indicators; (ii) Collection of information need for policy making, e.g. through consultation actions and surveys. The general objective of TAIPI is to support and strengthen the FET Flagship Initiative and the two selected Flagships. Specific objectives of TAIPI are: (i) To develop assessment methodologies along with the required toolkits which will be applied respectively to HBP and Graphene Flagships, (ii) To carry out the impact assessment of both Flagships and the Flagship policy by applying the specifically developed methodology and tools, (iii) To collect and provide information for policy makers and funding organizations participating to Flagships initiative, (iv) To transfer to the Flagships these developed toolkits, and to enable them to use these tools after the end of the CSA, thus ensuring the sustainability of the project activities. TAIPI is composed of 5 work packages: WP1 Management, WP2 Development of methodology, WP3 Impact assessment, WP4 Support to policy makers, WP5 Dissemination. TAIPI will assess the impacts of HBP and Graphene, enhance the flow of information from the Flagships towards policy makers, relevant stakeholders and wider public, improve the understanding of the impacts of the Flagships on science, technology, economy and society and contribute to create a stable and structured environment for the benefit of the FET Flagships. The environment created by TAIPI will thus benefit to the Flagships, allowing them to concentrate on the fields where they bring the highest added value to their stakeholders while they rely on up-to-date tools, developed by TAIPI, to monitor in real time their impacts.
To reach the targets of the Paris Agreement commitments for land degradation neutrality, for biodiversity, and to support the EU Green Deal, Europe needs to join its research and innovation forces on soil carbon with those around the globe in a coordinated manner. To scale up efforts for conserving and increasing soil carbon stocks and harness the co-benefits for climate change mitigation and adaptation, soil health and food security international coordination of research efforts is essential. In this context the EC supported a 1st Coordination action (CIRCASA) led by INRAE which brought together over 100 key stakeholders and 500 scientists from around the world who formalised an interest in establishing an International Research Consortium (IRC) on Soil Carbon built around an initial strategic research and innovation agenda (SRIA) focusing on agricultural soils. Operationalising the IRC requires further mobilization of the international community of stakeholders working on agricultural soil carbon but also other land uses and therefore expanding the initial SRIA as well as developing with international funding bodies an implementation plan and a central knowledge platform offering services to this community. The main goal of ORCaSa is therefore to launch and roll out the initial operational phases of the IRC on Soil Carbon so that by 2024 the IRC has established an international position as the coordinator of soil carbon research and innovation and related issues at global level offering a unique SRIA and implementation plan, supporting knowledge platform and enable the preparation of a disruptive low cost international recognized MRV system. To reach this overall goal, ORCaSa brings together European partners and 6 regional nodes covering the 5 continents around an ambitious 3-year work plan working hand in hand with the international every step of the way.